Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBI-778 in EGFR Mutated NSCLC, IDH Mutated Glioma, and ACC
NCT07755397Phase 1Recruiting
- Sponsor
- Jubilant Therapeutics Inc.
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JBI-778 in non-small cell lung cancer (NSCLC), glioma and adenoid cystic carcinoma (ACC), sponsored by Jubilant Therapeutics Inc. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Aug 2024; status: recruiting.
02
Drugs
JBI-778
03
Conditions
non-small cell lung cancer (NSCLC)gliomaadenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT07755397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07755397.